PF-Atlas › Clinical Trials › NCT03061331

Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

LUM/IVA · Phase 2

Registry ID
NCT03061331
Phase
Phase 2
Status
Completed
Drug / intervention
LUM/IVA
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2017-01-31
Enrollment
20
Locations
2

About this trial

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter, crossover study that will evaluate the efficacy of LUM/IVA in subjects with CF 12 years of age and older who have at least one A455E mutation.

View NCT03061331 on ClinicalTrials.gov →

Explore related

All LUM/IVA trialsAll IPF trials

Related trials

LUM/IVA — NCT02875366LUM/IVA — NCT02797132LUM/IVA — NCT03125395
Medical disclaimer. This page summarizes public trial data for NCT03061331 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.